We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Biodegradable Hernia Repair Device

By HospiMedica staff writers
Posted on 25 Jan 2006
A new medical device for hernia repair incorporates biodegradable technology to help the body repair itself. More...


The device, manufactured by TyRx Pharma (Monmouth Junction, New Jersey, USA), consists of a surgical mesh coated with a polymer based on a bioresorbable technology developed at Rutgers University's (New Jersey, USA) New Jersey Center for Biomaterials (CBM). The polymer gives the surgical mesh improved handling characteristics that facilitate precise placement during the surgical repair and leave less implant material following the resorption of the coating. The device has been approved by the U.S. Food and Drug Administration (FDA).

The polymer used is one in a series, or library, of novel tyrosine-based polyarylates. Polyarylates arose from an adaptation of combinatorial chemistry to biomaterials. Two sets of starting materials are combined with each other in all possible combinations. In this way, a large variety of related polymers from a small number of initial starting materials can be produced. TyRx has licensed the entire 112 structurally related library of polyarylates from Rutgers, each one potentially useful in a wide range of medical implant applications.

"There are only a handful of synthetic, degradable polymers that have an FDA approval history. Therefore, the approval of the TyRx device employing a new biomaterial represents a major breakthrough for regenerative medicine. said Joachim Kohn, CBM director and professor of chemistry and chemical biology at Rutgers.




Related Links:
TyRx Pharma
Rutgers University

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.